JRSS JRSIS HEALTH CARE Corp
Services-Hospitals · OTC · SEC CIK 1597892 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-100.5%
TTM EPS YoY-100.1%
Revenue 3-yr CAGR-52.4%
Net income 3-yr CAGR—
Margins
Gross margin9.4%
Operating margin-7.0%
Net margin-3.7%
FCF margin—
EBITDA margin-6.4%
Returns
ROE-125.7%
ROA-13.2%
ROIC (approx.)-171.2%
Asset turnover3.58x
Leverage & solvency
Liabilities / assets111.3%
Debt / equity—
Current ratio0.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.67x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $222,922 | $597,396 | $500,420 | $3.41M | $497,361 | $337,395 | $476,994 | — |
| Cost of revenue | $196,037 | $411,284 | $443,198 | $1.98M | $377,252 | $297,784 | $325,602 | — |
| Gross profit | $26,885 | $186,112 | $57,222 | $171,939 | $120,109 | $39,611 | $151,392 | — |
| R&D expense | $28,840 | $9,599 | $10,254 | $84,425 | $36,202 | $38,344 | $30,295 | — |
| SG&A expense | $97,359 | $186,491 | $101,112 | $163,483 | $22,538 | $118,796 | $31,232 | — |
| Operating income | -$206,190 | -$118,718 | -$160,906 | $154,704 | $51,011 | -$127,283 | $77,524 | -$43,820 |
| Interest expense | — | $15,984 | $11,906 | — | — | $14,018 | $19,738 | — |
| Pretax income | -$219,970 | -$116,847 | -$169,948 | $257,689 | $39,284 | -$124,060 | $61,418 | -$45,561 |
| Income tax | $7 | $2,908 | — | $918 | -$123 | -$103 | $8,283 | — |
| Net income | -$188,146 | -$102,435 | -$145,356 | $262,390 | $33,705 | -$106,020 | $45,446 | $36.01M |
| EBITDA | -$203,493 | -$116,079 | -$148,709 | $167,340 | $54,849 | -$122,858 | $91,927 | -$41,695 |
| EPS (basic) | -0.00 | -0.00 | -0.00 | — | 0.00 | -0.00 | 0.00 | — |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | — | 0.00 | -0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 84.60M | 84.60M | 84.33M | — | 76.76M | 76.76M | 76.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1,372 | $445,902 | $323,611 | $118,114 | $741 | $423,519 | $4,638 | $158,813 |
| Receivables | $575,205 | $555,837 | $603,022 | $714,658 | — | $13,791 | — | $683,452 |
| Inventory | $361,774 | $397,825 | $445,500 | $455,240 | — | — | — | $562,015 |
| Current assets | $1.79M | $1.83M | $1.82M | $1.83M | $527,151 | $617,602 | $676,348 | $1.66M |
| PP&E, net | $43,162 | $43,265 | $46,193 | $50,024 | $30,844 | $33,051 | $37,028 | $62,223 |
| Intangibles | $241,146 | $242,178 | $243,897 | $257,334 | — | — | — | $303,195 |
| Total assets | $2.07M | $2.11M | $2.11M | $2.14M | $564,700 | $661,383 | $728,863 | $2.04M |
| Current liabilities | $2.30M | $2.11M | $2.40M | $2.28M | $90,969 | $69,393 | $36,968 | $2.11M |
| Short-term debt | $25,243 | $24,376 | $24,534 | $18,713 | — | — | — | $49,709 |
| Long-term debt | $6,311 | $12,188 | $18,401 | $24,950 | — | — | — | — |
| Total debt | $31,554 | $36,564 | $42,935 | $43,663 | — | — | — | — |
| Total liabilities | $2.31M | $2.13M | $2.42M | $2.31M | $90,969 | $69,393 | $36,968 | $2.11M |
| Shareholders' equity | -$197,594 | -$7,401 | -$259,933 | -$137,406 | $473,731 | $591,990 | $691,895 | -$58,453 |
| Net debt | $30,182 | -$409,338 | -$280,676 | -$74,451 | — | — | — | — |
| Shares outstanding | 84.60M | 84.60M | 84.60M | 82.59M | 5.84M | 5.84M | 58.37M | 76.76M |
| Cash flow statement | ||||||||
| Operating cash flow | -$352,266 | -$268,858 | -$204,937 | $536,904 | -$90,031 | $527,504 | -$16,507 | -$4.76M |
| Capital expenditure | $67,633 | — | — | $1,235 | -$358,535 | — | — | -$1,723 |
| Free cash flow | -$419,899 | — | — | $535,669 | $268,504 | — | — | -$4.76M |
| Investing cash flow | -$22 | — | — | $19,134 | — | — | — | $1,723 |
| Financing cash flow | -$95,807 | $402,570 | $413,267 | $7,877 | -$349,819 | -$83,248 | -$143,175 | $2.60M |
| Depreciation & amortization | $2,697 | $2,639 | $12,197 | $12,636 | $3,838 | $4,425 | $14,403 | $2,125 |
| Stock-based compensation | — | — | — | — | $81,822 | $81,822 | $81,821 | $81,822 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.